Improving treatment outcomes for patients with chronic inflammatory diseases through identification of predictive biomarkers and therapeutic drug monitoring of new biologicals KU Leuven
Psoriasis and inflammatory bowel diseases (IBD), with Crohn’s disease (CD) and ulcerative colitis (UC) being the two main subtypes, are chronic inflammatory diseases of the skin and gastrointestinal tract, respectively. Together, these lifelong debilitating diseases affect up to 4% of the Western population and typically have a relapsing-remitting disease course that significantly impacts the patient’s quality of life. With the introduction ...